The most dangerous window in severe depression occurs during the four to eight week lag before conventional antidepressants take effect, a vulnerable period where suicide risk peaks. A breakthrough randomized controlled trial demonstrates that frontline add-on intravenous ketamine completely eliminates this agonizing delay, delivering meaningful clinical relief within 48 hours.
Discover how just four infusions achieved a 58% response rate, cleared suicidal ideation to absolute zero within five days, and sustained recovery at four weeks. We also unpack the vital anxiety paradox that dictates who should, and who should not, receive this rapid intervention. Tune in to explore how emergency psychiatry can shift from passive observation into proactive, rapid neuroplastic healing.
Resources: Prakash, A., Mahapatra, P., Pattnaik, J. I., Panda, U. K., & Das, S. K. (2026). Add-on intravenous ketamine eliminates treatment lag period in severe non-treatment-resistant major depression: Rapid antidepressant and anti-suicidal effects – A randomized controlled trial. *Indian Journal of Psychiatry*, *68*(9), 776–783. https://doi.org/10.4103/indianjpsychiatry_845_25
Podden och tillhörande omslagsbild på den här sidan tillhör
Talking Ketamine. Innehållet i podden är skapat av Talking Ketamine och inte av,
eller tillsammans med, Poddtoppen.
